Discovery and SAR Study of Boronic Acid-Based Selective PDE3B Inhibitors from a Novel DNA-Encoded Library.

Human genetic evidence shows that PDE3B is associated with metabolic and dyslipidemia phenotypes. A number of PDE3 family selective inhibitors have been approved by the FDA for various indications; however, given the undesirable proarrhythmic effects in the heart, selectivity for PDE3B inhibition over closely related family members (such as PDE3A; 48% identity) is a critical consideration for development of PDE3B therapeutics. Selectivity for PDE3B over PDE3A may be achieved in a variety of ways, including properties intrinsic to the compound or tissue-selective targeting. The high (>95%) active site homology between PDE3A and B represents a massive obstacle for obtaining selectivity at the active site; however, utilization of libraries with high molecular diversity in high throughput screens may uncover selective chemical matter. Herein, we employed a DNA-encoded library screen to identify PDE3B-selective inhibitors and identified potent and selective boronic acid compounds bound at the active site.

Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors.

Herein we report the discovery of pyrazolocarboxamides as novel, potent, and kinase selective inhibitors of receptor interacting protein 2 kinase (RIP2). Fragment based screening and design principles led to the identification of the inhibitor series, and X-ray crystallography was used to inform key structural changes. Through key substitutions about the N1 and C5 N positions on the pyrazole ring significant kinase selectivity and potency were achieved. Bridged bicyclic pyrazolocarboxamide 11 represents a selective and potent inhibitor of RIP2 and will allow for a more detailed investigation of RIP2 inhibition as a therapeutic target for autoinflammatory disorders.

STING Activation and its Application in Immuno-Oncology.

Recent regulatory approval of several immune checkpoint inhibitors has ushered in a new era of cancer immunotherapies with the promise of achieving a durable response. This represents a paradigm shift in cancer treatment from directly targeting tumor cells to harnessing the power of a patient's own immune system to destroy them. The cGAS-STING pathway is the major cytosolic dsDNA sensing pathway that plays a pivotal role in the innate antitumor immune response. With a fundamentally different mode of action (MOA) than immune checkpoint modulators, STING activation can potentially enhance tumor immunogenicity and improve patient responses as a single agent or by synergizing with existing anti-cancer drugs. Therefore, there has been intense interest from the pharmaceutical industry and academic institutions in the search for potent STING agonists as immunotherapies in oncology. In this article, we review briefly the cGAS-STING pathway and STING agonists that are in the clinical and preclinical studies, summarize recently disclosed patent applications and published journal articles in the field and cover both cyclic dinucleotide (CDN) analogs and non-nucleic acid derived STING agonists.

Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activity.

Change history: In this Letter, author Ana Puhl was inadvertently omitted; this error has been corrected online.An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Design of amidobenzimidazole STING receptor agonists with systemic activity.

Stimulator of interferon genes (STING) is a receptor in the endoplasmic reticulum that propagates innate immune sensing of cytosolic pathogen-derived and self DNA1. The development of compounds that modulate STING has recently been the focus of intense research for the treatment of cancer and infectious diseases and as vaccine adjuvants2. To our knowledge, current efforts are focused on the development of modified cyclic dinucleotides that mimic the endogenous STING ligand cGAMP; these have progressed into clinical trials in patients with solid accessible tumours amenable to intratumoral delivery3. Here we report the discovery of a small molecule STING agonist that is not a cyclic dinucleotide and is systemically efficacious for treating tumours in mice. We developed a linking strategy to synergize the effect of two symmetry-related amidobenzimidazole (ABZI)-based compounds to create linked ABZIs (diABZIs) with enhanced binding to STING and cellular function. Intravenous administration of a diABZI STING agonist to immunocompetent mice with established syngeneic colon tumours elicited strong anti-tumour activity, with complete and lasting regression of tumours. Our findings represent a milestone in the rapidly growing field of immune-modifying cancer therapies.

Highly stereoselective and iterative synthesis of alpha-(1-->4)-linked polysaccharides composed of 3-O-methyl-D-mannose.

A second-generation synthesis of synthetic 3-O-methyl-D-mannose-containing polysaccharides (sMMPs) is reported. The glycosidation of donor B and acceptor C, prepared from a common precursor A in two and one steps, respectively, is effected by t-butyldimethylsilyl trifluoromethanesulfonate to furnish only the desired alpha-anomer D in high yields. Unlike the first-generation synthesis, this synthesis gives the desired product free from contamination of scrambling products. A three-step protocol is used to deprotect D to furnish sMMPs.

Practical and scalable synthesis of alpha-(1-->4)-linked polysaccharides composed of 6-O-methyl-D-glucose.

A second-generation synthesis of synthetic 6-O-methyl-D-glucose-containing polysaccharides (sMGPs) is reported. Glycosidation acceptor A and donor B are prepared from alpha-, beta-, and gamma-cyclodextrins in high yields. The glycosidation of A and B, followed by deprotection, furnishes sMGP 12-, 14-, and 16-mers. This synthesis has appealing features such as scalability, operational simplicity, and high overall yield.

Iron in the service of chromium: the ortho-benzannulation of trans,trans-dienyl Fischer carbene complexes.

Chromium Fischer carbene complexes with trans,trans-dienyl substituents on the carbene carbon will react with diiron nonacarbonyl to give 2-alkoxycyclohexa-2,4-dienone iron tricarbonyl complexes and/or 2-alkoxyphenols in excellent yields. In the presence of silica gel or base, the cyclohexadienone complex will suffer loss of the iron and aromatization to give 2-alkoxyphenols. The formation of 2-alkoxyphenols from dienyl chromium carbene complexes is a known process (ortho-benzannulation) that only occurs with certain cis,trans-dienyl complexes. Control experiments show that trans,trans-dienyl chromium carbene complexes do not undergo conversion to 2-alkoxyphenols in the absence of an iron source. The process most likely occurs either via coordination of the dienyl unit in the chromium carbene complex to an iron tricarbonyl group and then loss of the chromium or via direct trans-metalation of the carbene ligand to give an iron carbene complex and then internal coordination to the dienyl unit such that cis to trans isomerization of the alpha,beta-double bond occurs.

Luminescence and structural comparisons of strong-acid sensor molecules. 2.

Anthraquinone-containing cyclic polyether hosts form 1:1 complexes with hydronium ion, producing large enhancements in luminescence via inversion of npi* and pipi* exited states. We have characterized the binding of hydronium ion within these host molecules and have synthesized a large variety of analogous hosts that contain different structural and electronic features that allow better understanding of what controls binding and luminescence capacity in this class of fluorescent sensor molecules. X-ray crystallography of an anthraquinone host that contains terminal amine functional groups rather than terminal ether groups is investigated, and complete proton transfer to carbonyl groups is observed in concentrated sulfuric acid media that also produces a previously unobserved luminescence.